GlassScriptPhysician profile
Melvinie E Seymore
NPI 1114097458
$170.24
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $15.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $32.71 | 2019 | |
| Gilead Sciences, INC. | $28.20 | 2019 | |
| Exeltis, USA INC. | $28.13 | 2019 | |
| Merck Sharp & Dohme LLC | $17.65 | 2019 | |
| Theratechnologies INC. | $15.39 | 2020 | |
| Allergan, INC. | $14.37 | 2019 | |
| Avion Pharmaceuticals | $11.83 | 2019 | |
| Minerva Surgical, INC | $11.17 | 2019 | |
| Pfizer INC. | $10.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvinie Seymore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.